1-8 of 8
James A. Hoxie
Close
Sort by
Journal Articles

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis

Clinical Trials & Observations
Ryan H. Moy, Austin P. Huffman, Lee P. Richman, Lisa Crisalli, Ximi K. Wang, James A. Hoxie, Rosemarie Mick, Stephen G. Emerson, Yi Zhang, Robert H. Vonderheide, David L. Porter, Ran Reshef
Journal: Blood
Blood (2017) 129 (7): 906–916.
https://doi.org/10.1182/blood-2016-08-735076
Published: 2017
Includes: Supplemental data
Journal Articles

Immunologic Effects of CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis

Ryan H Moy, MD PhD, Austin P Huffman, BA, Lee P Richman, BA, Lisa Crisalli, BS, James A Hoxie, MD, Robert H Vonderheide, MD DPhil, David L Porter, MD, Ran Reshef, MD
Journal: Blood
Blood (2015) 126 (23): 920.
https://doi.org/10.1182/blood.V126.23.920.920
Published: 2015
Journal Articles

Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II Study

Ran Reshef, MD, James K. Mangan, MDPhD, Selina M. Luger, MD, Alison Wakoff Loren, MDMS, Elizabeth O. Hexner, MD, Noelle V. Frey, MDMS, Edward A. Stadtmauer, MD, Robin E. Blauser, BSN RN, Lee P. Richman, BA, Austin P. Huffman, BA, Alex Ganetsky, PharmD, Edward P. Acosta, PharmD, James A. Hoxie, MD, Rosemarie Mick, MS, Robert H. Vonderheide, MDDPhil, David L. Porter, MD
Journal: Blood
Blood (2014) 124 (21): 2491.
https://doi.org/10.1182/blood.V124.21.2491.2491
Published: 2014
Journal Articles

Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist – Final Results of a Phase I/II Study

Ran Reshef, MD, Selina M. Luger, MD, Elizabeth O. Hexner, MD, Alison W. Loren, MD, Noelle V. Frey, MD, Steven C. Goldstein, MD, Sunita D. Nasta, MD, Edward A. Stadtmauer, MD, Jacqueline Smith, CRNP, Rosemarie Mick, MS, Daniel F. Heitjan, PhD, James A. Hoxie, MD, Stephen G. Emerson, MD, PhD, Robert H. Vonderheide, MD, PhD, David L. Porter, MD
Journal: Blood
Blood (2011) 118 (21): 1011.
https://doi.org/10.1182/blood.V118.21.1011.1011
Published: 2011
Journal Articles

Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5

Brief Report
Heather A. Pilch-Cooper, Scott F. Sieg, Thomas J. Hope, Ann Koons, Jean-Michel Escola, Robin Offord, Ronald S. Veazey, Donald E. Mosier, Brian Clagett, Kathy Medvik, Julie K. Jadlowsky, Mark R. Chance, Janna G. Kiselar, James A. Hoxie, Ronald G. Collman, Nadeene E. Riddick, Valentina Mercanti, Oliver Hartley, Michael M. Lederman
Journal: Blood
Blood (2011) 118 (4): 1015–1019.
https://doi.org/10.1182/blood-2010-05-282509
Published: 2011
Includes: Supplemental data
Journal Articles

Prevention of Graft-Versus-Host Disease by Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist

Ran Reshef, MD, Selina M. Luger, MD, Alison W. Loren, MD, Noelle V. Frey, MD, Steven C. Goldstein, MD, Elizabeth O. Hexner, MD, Edward A. Stadtmauer, MD, Jacqueline Smith, CRNP, Rosemarie Mick, MS, Daniel F. Heitjan, PhD, Susan E. Shetzline, PhD, Gwenn-ael H. Danet-Desnoyers, PhD, Stephen G. Emerson, MD, PhD, James A. Hoxie, MD, Robert H. Vonderheide, MD, PhD, David L. Porter, MD
Journal: Blood
Blood (2010) 116 (21): 673.
https://doi.org/10.1182/blood.V116.21.673.673
Published: 2010
Journal Articles

Vaccine-delivered HIV envelope inhibits CD4 + T-cell activation, a mechanism for poor HIV vaccine responses

Kathy Fernando, Haitao Hu, Houping Ni, James A. Hoxie, Drew Weissman
Journal: Blood
Blood (2006) 109 (6): 2538–2544.
https://doi.org/10.1182/blood-2006-08-038661
Published: 2006
Journal Articles

Human Immunodeficiency Virus-1 Entry Into Purified Blood Dendritic Cells Through CC and CXC Chemokine Coreceptors

Seyoum Ayehunie, Eduardo A. Garcia-Zepeda, James A. Hoxie, Richard Horuk, Thomas S. Kupper, Andrew D. Luster, Ruth M. Ruprecht
Journal: Blood
Blood (1997) 90 (4): 1379–1386.
https://doi.org/10.1182/blood.V90.4.1379
Published: 1997